SRPT | tickerfilter.com

Fundamental analysis

42%

Profitability 25%

Dept financing 29%

Liquidity 75%

Performance 55%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

1.18%

1 Month

20.95%

3 Months

0.23%

6 Months

-8.27%

1 Year

-61.22%

2 Year

-81.69%

Key data

Stock price

$21.42

P/E Ratio

N/A

DAY RANGE

$20.81 - $21.49

EPS

-$7.13

52 WEEK RANGE

$10.42 - $64.80

52 WEEK CHANGE

-$63.88

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

104.990 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

08-06-2025

BETA

1.32

PUBLIC FLOAT

AVERAGE 10 VOLUME

$2,374,098

AVERAGE 30 VOLUME

$3,491,676

Company detail

CEO: Douglas S. Ingram
Region: US
Website: sarepta.com
Employees: 840
IPO year: 1997

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio.

SRPT - Sarepta Therapeutics, Inc.